AbCellera Biologics Inc. (ABCL)

Every figure this model derived for ABCL, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 24,734,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 120,065,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 679,230,000 AssetsCurrent 2026-06-30
current liabilities 53,189,000 LiabilitiesCurrent 2026-06-30
equity 896,020,000 StockholdersEquity 2026-06-30
ocf -94,937,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 66,173,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 51,098,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ABCL on one particular measure came for.

RatioValue
cash operating margin-230.54
current ratio20.91
current ratio reported12.77
deferred revenue growth22.16
dilution pct1.49
fcf margin-180.85
growth cv3.15
operating margin-340.25
owner earnings margin-258.06
revenue growth101.28
revenue growth per share98.33
roic-22.92
rule of 40-238.97
sbc pct revenue77.22

What to be careful about

What this model itself distrusts about ABCL's figures. Written by the derivation as it ran, not added afterwards.